Monzer Yazji, MD
Internal Medicine · Edinburg, TXNPI 1619998838
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $67,355 of the $72,048 with a category attached, or 93.5%. Novo Nordisk accounts for 98.7% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $30,979 and has fallen 99.9% since, to $20 in 2025. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 110 payments — averaging $654.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$71K
- Baxter Healthcare$270
- Lilly USA, LLC$110
- Galderma Laboratories, L.p.$91
- Kowa Pharmaceuticals America, Inc.$86
- AbbVie$78
- plus $316 from 12 others
Across 75 payments — averaging $21,147 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- BD$965K
- Bavarian Nordic A/s$580K
- Teva Pharmaceuticals USA, Inc.$25K
- Partner Therapeutics, Inc.$11K
- Shionogi Inc$5K
What the payments were for
- Speaking & faculty fees$67,35593%
- Travel & lodging$2,1563%
- Food & beverage$2,2553%
- Education$120%
- Other$2700%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 74 | $71,097 |
| Baxter Healthcare | 1 | $270 |
| Lilly USA, LLC | 7 | $110 |
| Galderma Laboratories, L.p. | 4 | $91 |
| Kowa Pharmaceuticals America, Inc. | 1 | $86 |
| AbbVie(2 entities) | 4 | $78 |
| AstraZeneca | 4 | $61 |
| Abbott | 3 | $45 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Mannkind Corporation | 2 | $34 |
| Amgen | 1 | $24 |
| Medtronic | 1 | $23 |
| Phadia US Inc. | 1 | $20 |
| Redhill Biopharma Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| GSK | 1 | $14 |
| Cumberland Pharmaceuticals, Inc. | 1 | $12 |
| Tactile Systems Technology Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$28,451
- Ozempic$21,982
- Tresiba$10,138
- Xultophy 100/3.6$1,875
How this compares
$72,048 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 15 | $15,394 |
| FarxigaDapagliflozin Propanediol | 12 | $13,640 |
| MyrbetriqMirabegron | 11 | $6,554 |
| Alcohol Prep PadsAlcohol Antiseptic Pads | 35 | $1,706 |
| Alcohol PadsAlcohol Antiseptic Pads | 16 | $1,509 |
| Atorvastatin Calcium | 96 | $907 |
| Rosuvastatin Calcium | 40 | $596 |
| Metformin Hcl | 73 | $431 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $382 |
| Losartan Potassium | 35 | $335 |
| Omeprazole | 47 | $323 |
| Lisinopril | 34 | $250 |
| Metoprolol Succinate | 21 | $175 |
| Montelukast Sodium | 21 | $175 |
| Lactulose | 12 | $156 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $71,097 | $15,39415 claims |
| AstraZenecaFarxiga | $61 | $13,64012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Edinburg
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.